While there are many ACE inhibitors in the market that block both domains, there are no clinically available drugs that selectively inhibit cACE (the dominant domain responsible for hypertension) or nACE (predominantly involved in fibrosis and inflammation in the heart, kidney, and lungs) [9]. This evidence concerns the gene ACE and Hypertension.